Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial.
George BakrisMegumi OshimaKenneth W MahaffeyRajiv AgarwalChristopher P CannonGeorge CapuanoDavid M CharytanDick de ZeeuwRobert EdwardsTom GreeneHiddo J L HeerspinkAdeera LevinBruce NealRichard OhCarol PollockNorman RosenthalDavid C WheelerHong ZhangBernard ZinmanMeg J JardineVlado PerkovicPublished in: Clinical journal of the American Society of Nephrology : CJASN (2020)
This post hoc analysis suggests canagliflozin slowed progression of kidney disease, without increasing AKI, even in participants with eGFR <30 ml/min per 1.73 m2.